Nanotechnology Now

Our NanoNews Digest Sponsors

Heifer International

Wikipedia Affiliate Button

Home > Press > NanoBio Announces Closing of $22 Million Series B Financing Round

Abstract:
Funds Will Support Clinical Trials and Ongoing Operations Through Early 2011

NanoBio Announces Closing of $22 Million Series B Financing Round

Ann Arbor, MI | Posted on July 8th, 2009

NanoBio Corp., a biopharmaceutical company developing dermatological products, anti-infective treatments and intranasal vaccines, announced today that it has closed a $22 million Series B financing round after recently securing an additional $10 million investment from NanoBio's majority shareholder Perseus, L.L.C., based in New York, NY, and Venture Investors of Madison, WI and Ann Arbor, MI. The $10 million is in addition to the $12 million Series B funding announced in February 2009. To date, NanoBio has received more than $90 million in equity and grant funding to support the development of the company's anti-infective products and nanoemulsion-based vaccines.

"This investment round secures our ability to independently fund the next two years of our operations," commented James R. Baker, Jr., MD, NanoBio's CEO and founder. "Our investors see the tremendous value of our platform technology from both a medical and commercial perspective. There is a clear need for novel topical anti-infective therapies and new vaccine-adjuvant approaches that offer safety, ease of use, and enhanced efficacy."

The funding will support the advancement of numerous clinical and preclinical programs, including the development of products for herpes labialis, onychomycosis, acne, and cystic fibrosis as well as intranasal vaccines for seasonal influenza and other diseases. The company will begin a Phase 1 clinical study in acne this summer and is planning to initiate a phase III study in herpes labialis. In addition, the company is currently conducting a Phase 1 clinical study in NB-1008, a seasonal influenza vaccine administered via a nasal dropper.

NB-1008 uses a novel nanoemulsion-based adjuvant to achieve a robust immune response using only a small fraction of the antigen required by currently available injectable vaccines. In numerous animal studies, NB-1008 has demonstrated robust mucosal, systemic and cellular immunity without inflammation or safety concerns.

"NanoBio is a compelling investment choice, offering a strong scientific basis supported by promising ongoing trial results," commented George Arida, managing director for Venture Investors' healthcare practice. "At a time when investors have a multitude of good companies seeking financing, we are selectively backing those with strong management teams and novel technology that have the potential to create significant change in the healthcare landscape."

####

About NanoBio Corp.
NanoBio® Corp. is a privately held biopharmaceutical company focused on developing and commercializing dermatological products, anti-infective treatments and intranasal vaccines derived from its patented NanoStat™ technology platform. The company’s lead dermatology and anti-infective product candidates include treatments for herpes labialis (cold sores), onychomycosis (nail fungus), acne, molluscum contagiosum, and cystic fibrosis. The company’s headquarters and laboratory facilities are located in Ann Arbor, Michigan.

For more information, please click here

Contacts:
2311 Green Road, Suite A
Ann Arbor, Michigan 48105
Telephone: 734.302.4000
Fax: 734.302.9150

V.P. Business Development
John Coffey (Ext. 107)

Copyright © NanoBio Corp.

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

ICN2 researchers compute unprecedented values for spin lifetime anisotropy in graphene November 17th, 2017

Math gets real in strong, lightweight structures: Rice University researchers use 3-D printers to turn century-old theory into complex schwarzites November 16th, 2017

The stacked color sensor: True colors meet minimization November 16th, 2017

Nanometrics to Participate in the 6th Annual NYC Investor Summit 2017 November 16th, 2017

Investments/IPO's/Splits

Nanometrics to Participate in the 6th Annual NYC Investor Summit 2017 November 16th, 2017

180 Degree Capital Corp. Leads Investment in TheStreet, Inc.; Investment Enables Removal of Capital Structure Overhang November 14th, 2017

Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Marketplace Rule 5635(c)(4) October 23rd, 2017

Arrowhead Hosts Investor & Analyst R&D Day to Introduce TRiM(TM) Platform and Lead RNAi-based Drug Candidates September 14th, 2017

Nanomedicine

Nanobiotix presented new clinical and pre-clinical data confirming NBTXR3’s significant potential role in Immuno-Oncology at SITC Annual Meeting November 14th, 2017

Arrowhead to Present at 29th Annual Piper Jaffray Healthcare Conference November 14th, 2017

A new way to mix oil and water: Condensation-based method developed at MIT could create stable nanoscale emulsions November 8th, 2017

Nanoshells could deliver more chemo with fewer side effects: In vitro study verifies method for remotely triggering release of cancer drugs November 8th, 2017

Announcements

ICN2 researchers compute unprecedented values for spin lifetime anisotropy in graphene November 17th, 2017

Math gets real in strong, lightweight structures: Rice University researchers use 3-D printers to turn century-old theory into complex schwarzites November 16th, 2017

The stacked color sensor: True colors meet minimization November 16th, 2017

Nanometrics to Participate in the 6th Annual NYC Investor Summit 2017 November 16th, 2017

Nanobiotechnology

Nanobiotix presented new clinical and pre-clinical data confirming NBTXR3’s significant potential role in Immuno-Oncology at SITC Annual Meeting November 14th, 2017

Arrowhead to Present at 29th Annual Piper Jaffray Healthcare Conference November 14th, 2017

Nanoshells could deliver more chemo with fewer side effects: In vitro study verifies method for remotely triggering release of cancer drugs November 8th, 2017

Age-old malaria treatment found to improve nanoparticle delivery to tumors: Nanomedicine researchers find new use for 70-year-old drug November 7th, 2017

NanoNews-Digest
The latest news from around the world, FREE



  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project